Epigenomics AG / Key word(s): Miscellaneous 01.10.2014 / 14:00 Epigenomics Provides Corporate Update Berlin (Germany) and Germantown, MD (U.S.A.), October 1, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today provides a corporate update on major developments. Epigenomics, in consultations with the U.S. Food and Drug Administration […]
Category: Press Releases
19. September 2014
Epigenomics AG: Epigenomics AG converts to registered shares
Epigenomics AG / Key word(s): Miscellaneous 19.09.2014 / 15:51 Berlin (Germany), Germantown, MD (U.S.A.), September 19, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, will convert its 13,510,892 bearer shares into registered shares effective Monday, September 22, 2014 at a ratio of 1:1. The conversion, which was […]
12. August 2014
Epigenomics AG: Epigenomics AG Announces H1 2014 and Q2 2014 Financial Results and Reports on Operational Highlights
Epigenomics AG / Key word(s): Half Year Results 12.08.2014 / 08:30 Berlin (Germany) and Germantown, MD (U.S.A.), August 12, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the second quarter and the first half of 2014 ending June 30. H1 2014 […]
01. July 2014
Epigenomics AG Provides Update on Regulatory Status and Information on Additional Clinical Study for Epi proColon(R) in the U.S.
Epigenomics AG / Key word(s): Study 01.07.2014 / 15:15 Press release Epigenomics AG Provides Update on Regulatory Status and Information on Additional Clinical Study for Epi proColon(R) in the U.S. Berlin (Germany), Germantown, MD (U.S.A.), July 1, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, reports on […]
24. June 2014
Epigenomics AG: Epigenomics AG Announces Publication of Results of Two U.S. Clinical Studies with its Blood-based Epi proColon(R) CRC Screening Test
Epigenomics AG / Key word(s): Miscellaneous 24.06.2014 / 09:00 Berlin (Germany), Germantown, MD (U.S.A.), June 24, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that results from its U.S. clinical validation study for its blood-based colorectal cancer (CRC) detection test Epi proColon(R) as well as […]
02. June 2014
Epigenomics AG: FDA Issues Response Letter for Epigenomics’ Colorectal Cancer Screening Blood Test Epi proColon(R) Requesting Further Data Pre-Approval
Epigenomics AG / Key word(s): Miscellaneous 02.06.2014 / 21:30 Meeting to discuss next steps with FDA scheduled in June FDA decision has no impact on commercialization of Septin9-based tests by LDT partners or existing commercial arrangements for Epi proColon(R) in other regions Company remains committed to offer highly efficient and convenient alternative for CRC screening […]